Under this new program, Protonify will provide cannabis researchers with complimentary access to its high-purity, pharmaceutical-grade cannabinoid ingredients including THC concentrate and THCA isolate.
NANOOSE BAY — Protonify Corporation, a global provider of cannabinoid ingredients, is launching a global cannabinoid research partnership campaign designed to engage researchers investigating the medicinal and therapeutic efficacy of delta-9-THC and THCA.
Under this new program, Protonify will provide cannabis researchers with complimentary access to its high-purity, pharmaceutical-grade cannabinoid ingredients including THC concentrate (96 per cent + purity) and THCA isolate that has proven stability in an odorless, tasteless powder format and purity levels that approach 100 per cent. These products are produced with Protonify’s patent-pending, organic chemistry-based process that is unlike any other cannabis extraction technique being used today.
“One of the greatest challenges that cannabis researchers face is the lack of consistent, high-quality cannabinoid inputs”, said Andrew Fisher, CEO of Protonify. “Cannabinoid ingredients that have been sourced from traditional cannabis extractors contain high levels of unknown impurities, are unstable, and critically, have different profiles from one batch to the next. Protonify solves these problems. We look forward to sharing our quality products with teams seeking to effectively advance global cannabinoid research.”